BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16255757)

  • 1. The -670A > G polymorphism in the promoter region of the FAS gene is associated with necrosis in periportal areas in patients with chronic hepatitis C.
    Aguilar-Reina J; Ruiz-Ferrer M; Pizarro MA; Antiñolo G
    J Viral Hepat; 2005 Nov; 12(6):568-73. PubMed ID: 16255757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of TNF-beta polymorphism with disease severity among patients infected with hepatitis C virus.
    Goyal A; Kazim SN; Sakhuja P; Malhotra V; Arora N; Sarin SK
    J Med Virol; 2004 Jan; 72(1):60-5. PubMed ID: 14635012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation.
    Ben-Ari Z; Pappo O; Druzd T; Sulkes J; Klein T; Samra Z; Gadba R; Tambur AR; Tur-Kaspa R; Mor E
    Cytokine; 2004 Jul; 27(1):7-14. PubMed ID: 15207246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Putative association of Fas and FasL gene polymorphisms with clinical outcomes of hepatitis B virus infection.
    Jung YJ; Kim YJ; Kim LH; Lee SO; Park BL; Shin HD; Lee HS
    Intervirology; 2007; 50(5):369-76. PubMed ID: 17938571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection.
    Yee LJ; Tang J; Herrera J; Kaslow RA; van Leeuwen DJ
    Genes Immun; 2000 Aug; 1(6):386-90. PubMed ID: 11196686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of tumour necrosis factor alpha promoter polymorphisms at position -308 and -238 with clinical characteristics of chronic hepatitis C.
    Dai CY; Chuang WL; Lee LP; Chen SC; Hou NJ; Lin ZY; Hsieh MY; Hsieh MY; Wang LY; Chang WY; Yu ML
    J Viral Hepat; 2006 Nov; 13(11):770-4. PubMed ID: 17052277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of in vivo blockade of Fas- and TNFR1-mediated hepatocyte apoptosis by the hepatitis C virus.
    Rubbia-Brandt L; Taylor S; Gindre P; Quadri R; Abid K; Spahr L; Negro F
    J Pathol; 2002 Aug; 197(5):617-23. PubMed ID: 12210081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative correlation between intrahepatic expression of hepatitis C antigens and apoptosis despite high-level expression of Fas and HLA antigens.
    Caronia S; McGarvey MJ; Goldin RD; Foster GR
    J Viral Hepat; 2004 Nov; 11(6):511-8. PubMed ID: 15500551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C.
    Hiramatsu N; Hayashi N; Katayama K; Mochizuki K; Kawanishi Y; Kasahara A; Fusamoto H; Kamada T
    Hepatology; 1994 Jun; 19(6):1354-9. PubMed ID: 7514559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet-derived growth factor gene polymorphism in recurrent hepatitis C infection after liver transplantation.
    Ben-Ari Z; Tambur AR; Pappo O; Sulkes J; Pravica V; Hutchinson I; Klein T; Tur-Kaspa R; Mor E
    Transplantation; 2006 Feb; 81(3):392-7. PubMed ID: 16477226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of the fas system in hepatitis C virus recurrence after liver transplantation.
    Crespo J; Rivero M; Mayorga M; Fabrega E; Casafont F; Gomez-Fleitas M; Pons-Romero F
    Liver Transpl; 2000 Sep; 6(5):562-9. PubMed ID: 10980054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mannose-binding lectin gene polymorphisms are not associated with susceptibility to hepatitis C virus infection in the Brazilian Amazon region.
    Vallinoto AC; da Silva RF; Hermes RB; Amaral IS; Miranda EC; Barbosa MS; Moia Lde J; Conde SR; Soares Mdo C; Lemos JA; Machado LF; Ishak MO; Ishak R
    Hum Immunol; 2009 Sep; 70(9):754-7. PubMed ID: 19540295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethnic differences in polymorphisms of tumor necrosis factor-alpha, interleukin-10, and transforming growth factor-beta1 genes in patients with chronic hepatitis C virus infection.
    Zein NN; Germer JJ; El-Zayadi AR; Vidigal PG
    Am J Trop Med Hyg; 2004 Apr; 70(4):434-7. PubMed ID: 15100460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the tumor necrosis factor (TNF)--Fas L and HCV in the development of hepatocellular carcinoma.
    Nada O; Abdel-Hamid M; Ismail A; El Shabrawy L; Sidhom KF; El Badawy NM; Ghazal FA; El Daly M; El Kafrawy S; Esmat G; Loffredo CA
    J Clin Virol; 2005 Oct; 34(2):140-6. PubMed ID: 16157266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus.
    Kanemitsu S; Ihara K; Saifddin A; Otsuka T; Takeuchi T; Nagayama J; Kuwano M; Hara T
    J Rheumatol; 2002 Jun; 29(6):1183-8. PubMed ID: 12064832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased hepatocyte fas expression and apoptosis in HIV and hepatitis C virus coinfection.
    Macias J; Japón MA; Sáez C; Palacios RB; Mira JA; García-García JA; Merchante N; Vergara S; Lozano F; Gómez-Mateos J; Pineda JA
    J Infect Dis; 2005 Nov; 192(9):1566-76. PubMed ID: 16206071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of CCR5-Delta 32 and CCR2-V64I polymorphisms in a cohort of Spanish HCV patients using real-time polymerase chain reaction and fluorescence resonance energy transfer technologies.
    Ruiz-Ferrer M; Barroso N; Antiñolo G; Aguilar-Reina J
    J Viral Hepat; 2004 Jul; 11(4):319-23. PubMed ID: 15230854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of serum soluble Fas, Fas ligand and fas in intrahepatic lymphocytes in chronic hepatitis C.
    Zaki Mel S; Auf FA; Ghawalby NA; Saddal NM
    Immunol Invest; 2008; 37(2):163-70. PubMed ID: 18300041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms.
    Cheong JY; Cho SW; Hwang IL; Yoon SK; Lee JH; Park CS; Lee JE; Hahm KB; Kim JH
    J Gastroenterol Hepatol; 2006 Jul; 21(7):1163-9. PubMed ID: 16824070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
    Raghuraman S; Abraham P; Daniel HD; Ramakrishna BS; Sridharan G
    J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.